Prognostic significance of ST6GalNAc-1 expression in patients with non-metastatic clear cell renal cell carcinoma

Qi Bai; Li Liu; Wei Xi; Jiajun Wang; Yu Xia; Yang Qu; Ying Xiong; Qilai Long; Jiejie Xu; Jianming Guo

doi:10.18632/oncotarget.11258

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prognostic significance of ST6GalNAc-1 expression in patients with non-metastatic clear cell renal cell carcinoma

Qi Bai, Li Liu, Wei Xi, Jiajun Wang, Yu Xia, Yang Qu, Ying Xiong, Qilai Long, Jiejie Xu _ and Jianming Guo

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:3112-3120. https://doi.org/10.18632/oncotarget.11258

Metrics: PDF 1791 views | HTML 1985 views | ?

Abstract

Qi Bai1,*, Li Liu1,*, Wei Xi1,*, Jiajun Wang1, Yu Xia1, Yang Qu1, Ying Xiong1, Qilai Long1, Jiejie Xu2, Jianming Guo1

1Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

2Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

*These authors have contributed equally to this work

Correspondence to:

Jiejie Xu, email: [email protected]

Jianming Guo, email: [email protected]

Keywords: clear cell renal cell carcinoma, α-GalNAc α-2, 6-sialyltransferase 1, nomogram, overall survival

Received: March 07, 2016 Accepted: July 18, 2016 Published: August 12, 2016

ABSTRACT

Background: Sialyltransferase ST6GalNAc-1 is highly expressed in tumor cells and associated with tumor aggressiveness and poor prognosis. In the present study, we aimed to investigate the clinical and prognostic significance of sialyltransferase ST6GalNAc-1 in patients with non-metastatic ccRCC.

Results: High expression of ST6GalNAc-1 in tumor tissue was an independent prognostic factor for overall survival (p<0.001) and recurrence free survival (p<0.001) in multivariate analysis. The nomograms could give better prediction for overall survival and recurrence free survival in ccRCC patients.

Methods: 264 patients diagnosed with non-metastatic clear cell renal cell carcinoma were enrolled in the present study. Immunohistochemical staining was performed on tissue microarrays to evaluate the intratumoral ST6GalNAc-1 expression. Kaplan-Meier method and Cox proportional hazard model were applied to assess the prognostic value of ST6GalNAc-1. Nomograms were generated to refine individual risk stratification in ccRCC patients.

Conclusion: ST6GalNAc-1 was an independent adverse prognostic factor for both overall survival and recurrence free survival in patients with non-metastatic ccRCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11258

Publication Alerts

Research Papers:

Prognostic significance of ST6GalNAc-1 expression in patients with non-metastatic clear cell renal cell carcinoma

Abstract